Deine Einschätzung
Syndax Pharmaceuticals Inc Aktie
Was spricht für und gegen Syndax Pharmaceuticals Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Syndax Pharmaceuticals Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | 1,32 % | -5,23 % | -0,71 % | 120,63 % | 16,48 % | 8,59 % | 12,10 % |
| Rockwell Medical Inc. | - | -0,74 % | 3,87 % | -19,10 % | 18,99 % | -49,24 % | -91,43 % |
| Pacira Pharmaceuticals | 0,00 % | 3,06 % | 4,66 % | -12,17 % | -6,48 % | -44,81 % | -64,25 % |
| Twist Bioscience Corp | -3,02 % | -6,18 % | 4,55 % | 25,02 % | 46,75 % | 222,83 % | -63,18 % |
Kommentare
News
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
DAFNA Capital Management reported selling 222,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.89 million based on
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average



